Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Voyager Therapeutics, Inc.VYGR · Entity 6271 | Chief Scientific Officer | January 11, 2019 | January 18, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Voyager Therapeutics, Inc.
Report date January 11, 2019 · Filed January 18, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 163,688 |
Reported balance
After 2019-01-11 transaction · row 1
1 source rowRow 1 · 2019-01-11 · Grant · Acquired 25,000 · Balance 163,688 F1: Consists of shares of common stock issuable under an aggregate of 25,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, January 11, 2019. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.10 · Expires 2029-01-11 | Direct | 50,000 |
Reported balance
After 2019-01-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-01-11 · Grant · Acquired 50,000 · Balance 50,000 F2: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, January 11, 2019. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of shares of common stock issuable under an aggregate of 25,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, January 11, 2019. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.
F2: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, January 11, 2019. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 11, 2019 Filed Jan 18, 2019 01:51 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $9.10 | $0.00 |
DisclosureSEC source: 0001104659-19-002348 · a4.xml · derivative · entry 2 Sah Dinah Ph.D. · CIK 0001711043 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-01-11 F2 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, January 11, 2019. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| January 11, 2019 Filed Jan 18, 2019 01:51 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-002348 · a4.xml · nonDerivative · entry 1 Sah Dinah Ph.D. · CIK 0001711043 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,688 F1 · shares: Consists of shares of common stock issuable under an aggregate of 25,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, January 11, 2019. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| March 07, 2018 Filed Mar 10, 2018 00:12 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $28.72 | $0.00 |
DisclosureSEC source: 0001104659-18-016415 · a4.xml · derivative · entry 1 Sah Dinah Ph.D. · CIK 0001711043 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2028-03-07 F1 · derivative.exercise_date: This stock option was issued pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of the Vesting Commencement Date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 23:00 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,063 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001104659-18-014162 · a4.xml · derivative · entry 9 Sah Dinah Ph.D. · CIK 0001711043 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,937 Underlying: Common Stock · 4,063 shares Expires 2027-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The reporting person's Form 3, filed on July 7, 2017, erroneously reported the vesting schedule of this option. This option is scheduled to vest over four years in equal monthly installments, with 1/48th of the shares underlying such option vesting on the one-month anniversary of February 8, 2017, and 1/48th of the shares underlying such option vesting monthly thereafter. This Form 4 also aggregates identical options which were reported separately on the reporting person's Form 3. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 23:00 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $11.09 | $0.00 |
DisclosureSEC source: 0001104659-18-014162 · a4.xml · derivative · entry 8 Sah Dinah Ph.D. · CIK 0001711043 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 5,000 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The reporting person's Form 3, filed on July 7, 2017, erroneously reported the vesting schedule of this option. This option is scheduled to vest over four years in equal monthly installments, with 1/48th of the shares underlying such option vesting on the one-month anniversary of February 1, 2016, and 1/48th of the shares underlying such option vesting monthly thereafter. This Form 4 also aggregates identical options which were reported separately on the reporting person's Form 3. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 23:00 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,376 | $0.00 Strike: $8.33 | $0.00 |
DisclosureSEC source: 0001104659-18-014162 · a4.xml · derivative · entry 7 Sah Dinah Ph.D. · CIK 0001711043 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,570 Underlying: Common Stock · 4,376 shares Expires 2025-08-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The reporting person's Form 3, filed on July 7, 2017, erroneously reported the vesting schedule of this option. This option is scheduled to vest over four years in equal monthly installments, with 1/48th of the shares underlying such option vesting on the one-month anniversary of August 1, 2015, and 1/48th of the shares underlying such option vesting monthly thereafter. This Form 4 also aggregates identical options which were reported separately on the reporting person's Form 3. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 23:00 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,184 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001104659-18-014162 · a4.xml · derivative · entry 6 Sah Dinah Ph.D. · CIK 0001711043 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,957 Underlying: Common Stock · 2,184 shares Expires 2025-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The reporting person's Form 3, filed on July 7, 2017, erroneously reported the vesting schedule of this option. This option is scheduled to vest over four years in equal monthly installments, with 1/48th of the shares underlying such option vesting on the one-month anniversary of January 1, 2015, and 1/48th of the shares underlying such option vesting monthly thereafter. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 23:00 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 15,623 | $30.00 | $468,690.00 |
DisclosureSEC source: 0001104659-18-014162 · a4.xml · nonDerivative · entry 5 Sah Dinah Ph.D. · CIK 0001711043 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,688 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 23:00 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | Exercise / conversionCommon Stock | 4,063 | $11.83 | $48,065.29 |
DisclosureSEC source: 0001104659-18-014162 · a4.xml · nonDerivative · entry 4 Sah Dinah Ph.D. · CIK 0001711043 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,311 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 23:00 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | Exercise / conversionCommon Stock | 5,000 | $11.09 | $55,450.00 |
DisclosureSEC source: 0001104659-18-014162 · a4.xml · nonDerivative · entry 3 Sah Dinah Ph.D. · CIK 0001711043 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 23:00 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | Exercise / conversionCommon Stock | 4,376 | $8.33 | $36,452.08 |
DisclosureSEC source: 0001104659-18-014162 · a4.xml · nonDerivative · entry 2 Sah Dinah Ph.D. · CIK 0001711043 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 23:00 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | Exercise / conversionCommon Stock | 2,184 | $7.27 | $15,877.68 |
DisclosureSEC source: 0001104659-18-014162 · a4.xml · nonDerivative · entry 1 Sah Dinah Ph.D. · CIK 0001711043 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.